Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (ETNA)

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer " ETNA (Evaluating Treatment With Neoadjuvant Abraxane)

The purpose of this study is to assess the efficacy of neoadjuvant weekly nab-paclitaxel followed by Adriamycin, Cyclophosphamide (AC) or Epirubicin, Cyclophosphamide (EC) or Fluorouracil,Epirubicin,Cyclophosphamide (FEC)compared with neoadjuvant weekly solvent-based paclitaxel followed by AC or EC or FEC in terms of rate of pathological complete remissions at surgery.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Paclitaxel; Drug: Abraxane

Detailed Description

In this study, eligible and consenting patients will be randomized to receive either 4 cycles of weekly abraxane (nab-paclitaxel) followed by 4 cycles of an anthracycline-containing regimen or 4 cycles of weekly paclitaxel followed by 4 cycles of an anthracycline-containing regimen.The anthracycline regimen (AC, EC or FEC) will be chosen by the investigator at the participating sites.

Before randomization patients will be stratified according to Disease stage [operable (tumor stage: T2N0-1; T3N0) and locally advanced (T3N1;T4, any N2-3)] and Tumor subtype [luminal B intermediate (HER2 negative, ER or PGR positive, Ki67 from 14% to 20%) vs luminal B high (HER2 negative, ER or PGR positive, Ki67 >20%) vs triple negative tumors (HER2 negative, ER negative and PgR negative, Ki67 any value)]. Tumor subtype will be confirmed at two selected referral laboratories.

Neoadjuvant chemotherapy will be followed by definite surgery and irradiation as per international and local guidelines.

During neoadjuvant chemotherapy patients will be assessed for safety and efficacy as detailed in the protocol.

After definite surgery patients will be followed for approximately 10 years according to local procedures

• Study Type: Interventional
• Enrollment (Actual): 632
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Royal Adelaide Hospital
    • Adelaide, South Australia, Australia, 500
      • Royal Adelaide Hospital
  • Victoria
    • East Melbourne, Victoria, Australia, 8006
      • Peter McCallum Cancer Centre
    • East Melbourne, Victoria, Australia, 8600
      • Peter MacCallum Cancer Centre Department of Surgical Oncology
    • Ringwood East, Victoria, Australia, 3135
      • Eastern Health Breast Cancer Research - Maroondah Breast Clinic
    • Ringwood East, Victoria, Australia, 3135
      • Eastern Health Breast Cancer Research Maroondah Breast Clinic
  • Western Australia
    • Perth, Western Australia, Australia, 6000
      • Royal Perth Hospital
    • Perth, Western Australia, Australia, 6000
      • Mount Hospital - Breast Clinical Trials Unit
• Germany
  • Augsburg, Germany, 86156
    • Klinikum Augsburg International Patient Service
  • Berlin, Germany, 14169
    • Frauenarzt-Zentrum-Zehlendorf
  • Bochum, Germany, 44791
    • Augusta-Kranken-Anstalt gGmbH Klinik für Hämatologie, Onkologie & Palliativmedizin
  • Erlangen, Germany, 91054
    • Universitätsklinikum Erlangen - Frauenklinik - Poliklinik
  • Frankfurt, Germany, 60389
    • Bethanien-Krankenhaus Onkologisches Zentrum
  • Frankfurt, Germany, 60389
    • Agaplesion Markus Hospital - Frankfurt
  • Hamburg, Germany, 20357
    • Mammazentrum - Hamburg am Krankenhaus Jerusalem
  • Hannover, Germany, 30177
    • Gynäkologisch-Onkologische Praxis
  • Köln, Germany, 50935
    • St.Elisabeth-Krankenhaus Brustzentrum
  • Munich, Germany, 80336
    • Interdisciplinary Oncology Center
  • Munich, Germany, 81925
    • Praxis Gynäkologie Arabella
  • Speyer, Germany, 67346
    • Onkologische Schwerpunktpraxis
• Italy
  • BG
    • Bergamo, BG, Italy, 24125
      • Cliniche Gavazzeni - Humanitas Gavazzeni
  • BO
    • Bologna, BO, Italy, 40138
      • Policlinico Sant'Orsola Malpighi
  • Ferrara
    • Cona, Ferrara, Italy, 44124
      • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna
  • GE
    • Genova, GE, Italy, 16132
      • IST San Martino
  • MB
    • Monza, MB, Italy, 20050
      • A.O. San Gerardo
  • MI
    • Legnano, MI, Italy, 20025
      • A.O. Ospedale Civile di Legnano
    • Milano, MI, Italy, 20133
      • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Milano, MI, Italy, 20132
      • Ospedale San Raffaele
    • Milano, MI, Italy, 20160
      • A.O. Ospedale Luigi Sacco
    • Milano, MI, Italy, 20162
      • A.O. Ospedale Niguarda Ca' Granda
  • PD
    • Camposampiero, PD, Italy, 35012
      • ULSS 15 Alta Padovana
  • PV
    • Pavia, PV, Italy, 27100
      • Fondazione IRCCS Policlinico San Matteo
  • RE
    • Reggio Emilia, RE, Italy, 42123
      • Arcispedale Santa Maria Nuova
  • UD
    • Udine, UD, Italy, 33100
      • Ospedale Santa Maria della Misericordia
  • VI
    • Vicenza, VI, Italy, 36100
      • Azienda ULSS 6 di Vicenza
• Russian Federation
  • St. Petersburg, Russian Federation
    • NN Petrov Research Institute of Oncology
• Singapore
  • Singapore, Singapore, 169610
    • National Cancer Centre Singapore
• Spain
  • A Coruña, Spain, 15009
    • Centro Oncológico de Galicia
  • Alicante, Spain, 03010
    • Hospital General Universitario de Alicante
  • Badalona, Spain, 08916
    • Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
  • Barcelona, Spain, 08003
    • Hospital del Mar
  • Barcelona, Spain, 08036
    • Hospital Clinic i Provencial
  • Caceres, Spain, 10003
    • Hospital San Pedro de Alcantara
  • Córdoba, Spain, 14004
    • Hospital Universitario Reina Sofia
  • Donostia, Spain, 20014
    • Onkologikoa
  • Jaen, Spain, 23007
    • Complejo Hospitalario de Jaén
  • La Coruna, Spain
    • Hospital Teresa Herrera (CHUAC)
  • Lleida, Spain, 25198
    • Hospital Universitari Arnau de Vilanove de Lleida
  • Madrid, Spain, 28046
    • Hospital La Paz
  • Madrid, Spain
    • MD Anderson Cancer Center Madrid
  • Madrid, Spain, 28009
    • Gregorio Marañon hospital
  • Murcia, Spain, 30080
    • J.M. Morales Meseguer, Universitary Hospital Marques in los Velez
  • Salamanca, Spain, 37007
    • Hospital Clinico Universitario de Salamanca
  • San Sebastián, Spain, 20080
    • Hospital Universitario Donostia
  • Sevilla, Spain, 41013
    • Hospital Virgen del Rocío
  • Sevilla, Spain, 41071
    • Hospital Universitario Virgen Macarena
  • Toledo, Spain
    • Hospital Virgen de la Salud
  • Valencia, Spain, 46009
    • Instituto Valenciano Oncologia
  • Valencia, Spain
    • Hospital Clinico Universita Valencia
  • Ávila, Spain, 05004
    • Hospital Nuestra Señora de Sonsoles
  • Aragon
    • Zaragoza, Aragon, Spain, 50009
      • Miguel Servet University Hospital
    • Zaragoza, Aragon, Spain, 50009
      • Hospital Clinico Lozano Blesa
  • Baleares
    • Palma de Mallorca, Baleares, Spain, 2002
      • Hospital Son Llàtzer Palma de Mallorca
  • Barcelona
    • Sabadell, Barcelona, Spain, 08208
      • Corporacio Sanitaria Parc Tauli
    • Terrassa, Barcelona, Spain, 08227
      • Consorci Sanitari de Terrassa
  • Madrid
    • Alcorcón, Madrid, Spain, 28922
      • Hospital Universitario Fundacion Alcorcon
  • Tenerife
    • La Laguna, Tenerife, Spain, 38320
      • Hospital Universitario de Canarias

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Female patients aged 18 years or older
• Histologically confirmed invasive unilateral breast cancer
• HER2-negative disease
• Known hormone receptor status (estrogen receptor [ER], progesterone receptor [PgR]), tumor grade and, if institutional standard permits, known Ki67 value
• Available paraffin-embedded tumor block taken at diagnostic biopsy for central confirmation of HER2 eligibility, hormone receptor status, Ki67 value and biomarker evaluation is mandatory
• One of the following clinical stages:
• T2, T3, T4 disease, triple negative (HER2, ER, PgR)
• T2, T3, T4 disease, ER or PgR positive and moderately differentiated or poorly differentiated tumor grade (G II-III)
• ECOG performance status 0 or 1
• Written informed consent to participate in the trial (approved by the Institutional Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study specific screening procedures
• Willing and able to comply with the protocol

Exclusion Criteria:

• Synchronous contralateral breast cancer or presence of metastatic disease (M1). Exception: contralateral insitu ductal cancer
• Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted
• Pregnant or lactating women.
• Women with childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception, for example abstinence, an intra-uterine device, or double barrier method of contraception
• Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy for the currently diagnosed breast cancer prior to study entry
• Previous investigational treatment for any condition within 4 weeks of randomization date
• Patients on therapy with a strong CYP3A4 inhibitor and on therapy with Warfarin (Coumadin)
• Previous or concomitant malignancy of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or in situ cervix cancer are generally eligible.
• Pre-existing motor or sensory neuropathy of grade > 1 for any reason
• Patients with a history of hypersensitivity due to drugs containing polyoxyethylene castor oil (Cremophor EL) (e.g., ciclosporin), or hardened castor oil (e.g., vitamin preparations for injection, etc.)
• Other serious illness or medical condition including: history of documented congestive cardiac failure; angina pectoris requiring anti-anginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension (e.g. systolic >180 mm Hg or diastolic >100 mm Hg; however, patients with hypertension which is well controlled on medication are eligible); clinically significant valvular heart disease; high-risk uncontrolled arrhythmias
• Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drugs
• Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes mellitus
• Hematology and biochemistry tests within normla limits
• Baseline left ventricular ejection fraction (LVEF) < 50% by echocardiography or multi-gated scintigraphic scan (MUGA)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Paclitaxel; Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles. AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles	Drug: Paclitaxel; Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles; Other Names: No specific brand name
Experimental: Abraxane; Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles. AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles	Drug: Abraxane; Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles; Other Names: Nab-paclitaxel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pathologic Complete Response (pCR)	To compare the rate of pathologic Complete Response (pCR, absence of invasive disease in breast and nodes (ypT0/ypTis, ypN0)) for abraxane (Abraxane®, abraxane) vs paclitaxel.	At the time of surgery: 40 months after the randomization of the first patient

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
clinical Overall Response (cOR)	To compare the rate of clinical overall response (cOR) after the first 4 cycles of abraxane vs paclitaxel and to compare the rate of cOR after the entire preoperative chemotherapy (i.e. before surgery) in the study arms of abraxane vs paclitaxel	At the time of surgery: 40 months after the randomization of the first patient
Event Free Survival (EFS)	To compare the Event Free Survival (EFS, i.e. disease progression while on primary therapy or disease recurrence after surgery) in the study arms of abraxane vs paclitaxel	5 years after the first patient in and 10 years after randomization of last patient in
Distant Event Free Survival (DEFS)	The distant event free survival (DEFS) is defined as the time from randomization to the first date of distant metastasis while on primary therapy or distant recurrence after surgery or death due to any cause. Patients who terminate the study without evidence of any of the above events will be censored at the date of their last follow-up tumor assessment	5 years after the first patient in and 10 years after randomization of last patient in
Local Event Free Survival	The local event free survival (LEFS) is defined as the time from randomization to the first date of local progression while on primary therapy or local recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS	5 years after the first patient in and 10 years after randomization of last patient in
Regional Event Free Survival	The regional event free survival (REFS) is defined as the time from randomization to the first date of regional progression while on primary therapy or regional recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS.	5 years after the first patient in and 10 years after randomization of last patient in
Overall Survival (OS)	The overall survival (OS) is defined as the time from randomization to the date of death. Patients alive at the end of study will be censored at their last contact date.	13 years from the date of first patient in
Safety and Tolerability	Patients will be assessed for adverse events by clinical examination, questioning for symptoms of toxicity, laboratory assessments, vital signs, ECG and LVEF. Neurological toxicity and other toxicities will be assessed throughout the study according the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0.	Each participant will be followed for the duration of treatment period, approximately 9 months

Collaborators and Investigators

• Sponsor: Fondazione Michelangelo
• Investigators: Study Chair: Luca Gianni, MD, San Raffaele Hospital, Milan

Publications and helpful links

General Publications

• Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzu D, De Fato R, Valagussa P, Tusquets I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.

Study record dates

Study Major Dates

• Study Start: April 1, 2013
• Primary Completion (Actual): September 1, 2016
• Study Completion (Actual): March 1, 2023

Study Registration Dates

• First Submitted: March 25, 2013
• First Submitted That Met QC Criteria: March 27, 2013
• First Posted (Estimated): April 2, 2013

Study Record Updates

• Last Update Posted (Actual): March 7, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: cancer; breast; HER2 negative; unilateral; non metastatic
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel; Albumin-Bound Paclitaxel
• Other Study ID Numbers: FM-12-B01; 2012-003481-41 (EudraCT Number)